Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

Tyrosine kinase inhibitors (TKIs) have dramatically improved the outcome of chronic myeloid leukemia (CML). Besides inhibiting target kinases in leukemic cells, 2nd generation TKI dasatinib also inhibits off-targets in immune effector cells resulting in atypical immune responses in some patients. Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreutzman, Anna, Ilander, Mette, Porkka, Kimmo, Vakkila, Jukka, Mustjoki, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106168/
https://www.ncbi.nlm.nih.gov/pubmed/25083322
http://dx.doi.org/10.4161/onci.28925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106168/
https://www.ncbi.nlm.nih.gov/pubmed/25083322
http://dx.doi.org/10.4161/onci.28925

Ejemplares similares